Both Sides Lay Cards on The Table on Drug Pricing

July 9, 2021 by Dan McCue
Both Sides Lay Cards on The Table on Drug Pricing
Pharmaceuticals are seen in North Andover, Mass.(AP Photo/Elise Amendola, file)

WASHINGTON – A trio of House Democrats, including House Speaker Nancy Pelosi, D-Calif., and Rep. Carolyn Maloney, D-N.Y., chair of the House Committee on Oversight and Reform, accused the nation’s largest pharmaceutical companies on Thursday of being more concerned with “self enrichment” than in the well-being of the customers who rely on them for prescription drugs.

Joined at a mid-afternoon press conference by Rep. Peter Welch, D-Vt., and patient advocates, the Democrats based their attacks on the industry on a new report, the seventh Maloney’s committee has issued on drug prices since it began investigating the issue 2 ½ years ago.

The findings of the latest report, Maloney said, are based on an analysis of the financial data of the 14 largest drug companies in the world.

What the committee found, the Democrats said, is that the leading drug companies have routinely spent more on stock buybacks, dividends to investors, and executive compensation than on research and development.

“This analysis also reveals that drug companies’ claims that reducing U.S. prescription drug prices will harm innovation is overblown,” Maloney said.

The participating members of Congress are pushing hard for the passage of H.R. 3, the Elijah E. Cummings Lower Drug Prices Now Act, which, among other things, empowers Medicare to negotiate directly with drug companies to lower prices. 

The press conference came at a time when Democrats appear committed to passing some form of legislation this year curbing prescription drug prices, but disagree considerably on the details.

The Congressional Budget Office has estimated that H.R. 3’s negotiation provisions would save taxpayers $456 billion over 10 years, Pelosi said.

She went on to assure reporters on the conference call that even with the Act in place, drug companies could maintain or even exceed their current research and development expenditures, if only they were willing to reduce their spending on buybacks, dividends and executive pay.

Pelosi said she plans to push the legislation through the House by budget reconciliation, which would mean it could pass the Senate without Republican backing.

In response Brian Newell, a spokesman for industry association PhRMA, said while the organization couldn’t speak to the specific examples cited in the report, “this partisan exercise is clearly designed to garner support for an extreme bill that will erode Medicare protections and access to treatments for seniors.” 

According to the report, between 2016 and 2020, the 14 companies under the microscope spent $577 billion on stock buybacks and dividends — $56 billion more than they spent on research and development during the same period.

“One company, Amgen, spent nearly six times as much on buybacks, dividends, and executive compensation as it did on R&D in 2018,” said Welch.

Meanwhile, the Democrats reported, from 2016 to 2020, compensation for the 14 companies’ top executives totaled $3.2 billion, with annual compensation growing by 14% over that five-year period. 

Some companies paid their CEOs tens of millions of dollars as they raised prices on drugs relied on by millions of Americans, Pelosi said. At the same time, the Democrats concluded, many of these companies actively sought to suppress generic and biosimilar competition “while continuing to raise prices.”

But PhRMA’s Newell begged to differ.

“Every year, biopharmaceutical research companies invest tens of billions of dollars in the research and development of new cures and treatments, as well as our significant investments in time and resources creating treatments and vaccines to combat the global pandemic,” he said.

“Nonpartisan experts have highlighted the fact that net prices for medicines are trending down while patients continue to struggle with high deductibles and other out-of-pocket costs. 

“We have put forward ideas that would lower costs at the pharmacy, while preserving choice, access and innovation. We are committed to working with policymakers on commonsense, bipartisan solutions that address the real challenges patients face. Working together we can make sure medicines are affordable and accessible for everyone,” Newell added.

A+
a-
  • Congress
  • PhRMA
  • prescription drug prices
  • reconciliation
  • In The News

    Health

    Voting

    Prescription Drugs

    December 8, 2023
    by Tom Ramstack
    White House Threatens to Penalize Pharma Companies for High Prices

    WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a... Read More

    WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a tough stance toward pharmaceutical companies charging high prices. If the Federal Trade Commission determines the prices are unreasonable, the new policy allows the federal government to... Read More

    December 4, 2023
    by Dan McCue
    Justices Appear Divided Over Purdue Pharma Bankruptcy Deal

    WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize... Read More

    WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize the Sackler family, its one-time owners, from civil lawsuits for their role in the opioid crisis.  The closely watched case is considered to be among the most... Read More

    November 28, 2023
    by Dan McCue
    FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    WASHINGTON — The Food and Drug Administration on Tuesday approved Ogsiveo tablets for adult patients with progressing desmoid tumors, a... Read More

    WASHINGTON — The Food and Drug Administration on Tuesday approved Ogsiveo tablets for adult patients with progressing desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive, invading surrounding structures and organs, causing pain and disability. Although surgical... Read More

    Obesity Drug Wegovy Cut Risk of Serious Heart Problems by 20%, Study Finds

    The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that... Read More

    The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients. The research is the first to document that an obesity medication can not only pare... Read More

    Mind-Altering Ketamine Becomes Latest Pain Treatment, Despite Little Research

    WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking... Read More

    WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a trendy psychedelic therapy. Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth... Read More

    November 1, 2023
    by Dan McCue
    FDA Approves Biosimilar for Treatment of Multiple Inflammatory Diseases

    WASHINGTON — The Food and Drug Administration on Tuesday approved Wezlana, a biosimilar interchangeable with Stelara for the treatment of... Read More

    WASHINGTON — The Food and Drug Administration on Tuesday approved Wezlana, a biosimilar interchangeable with Stelara for the treatment of multiple inflammatory diseases. The agency said its approval of Wezlana, which is manufactured by Amgen, was based on a comprehensive review of scientific evidence demonstrating that... Read More

    News From The Well
    scroll top